Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Author:
- 29 January 2012
- journal article
- review article
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 66 (4) , 356-368
Abstract
To describe the efficacy and safety of vilazodone for the treatment of major depressive disorder (MDD). The pivotal registration trials were accessed by querying http://www.ncbi.nlm.nih.gov/pubmed/, http://www.fda.gov and http://www.clinicaltrials.gov for the search term 'vilazodone'. Product labeling provided additional information. All available clinical reports of studies were identified. Descriptions of the principal results and calculation of number needed to treat (NNT) and number needed to harm (NNH) for relevant dichotomous outcomes were extracted from the available study reports and other sources of information. Vilazodone is a specific serotonin reuptake inhibitor and serotonin 5HT1A receptor partial agonist. In needs to be administered with food to ensure adequate bioavailability. Approval for the treatment of MDD was based on a clinical development programme that included two 8-week placebo-controlled randomised clinical trials in outpatients with MDD where vilazodone was titrated to a target dose of 40 mg/d over the first 2 weeks. Both trials evidenced efficacy for vilazodone as measured by the Montgomery Asberg Depression Rating Scale. NNT for response vs. placebo was 8 (95% CI 6-16) and for remission was 14 (95% CI 8-55). NNH vs. placebo for discontinuation because of an adverse event (AE) was 27 (95% CI 15-104). The most commonly encountered AEs (incidence ≥ 5% and at least twice the rate of placebo) were diarrhoea, nausea, vomiting and insomnia, with NNH values vs. placebo of 6 (95% CI 5-8), 6 (95% CI 5-8), 30 (95% CI 18-82) and 26 (95% CI 16-78), respectively. NNH vs. placebo for any sexual AE was 12 (95% CI 9-18), but systematically collected data using rating scales of sexual function did not reveal treatment associated effects. Vilazodone was not associated with clinically relevant weight change in the short-term trials. In an open-label 1-year study of vilazodone, mean weight increased by 1.7 kg among the observed cases. Vilazodone represents another option for the treatment of MDD. Vilazodone appears to have a favourable weight-gain profile based on short-term studies. Sexual side-effects were not consistently demonstrated when assessed using clinical rating scales but spontaneously reported AEs related to sexual functioning were observed. Additional controlled data regarding long-term efficacy and effectiveness will help characterise this new agent when used in maintenance treatment.Keywords
This publication has 20 references indexed in Scilit:
- A 1-Year, Open-Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive DisorderJournal of Clinical Psychopharmacology, 2011
- VilazodoneThe Journal of Clinical Psychiatry, 2011
- A Randomized, Double-Blind, Placebo-Controlled, 8-Week Study of Vilazodone, a Serotonergic Agent for the Treatment of Major Depressive DisorderThe Journal of Clinical Psychiatry, 2011
- Antidepressants and Body WeightThe Journal of Clinical Psychiatry, 2010
- Adjunctive Aripiprazole, Olanzapine, or Quetiapine for Major Depressive Disorder: An Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or HarmedPostgraduate Medicine, 2010
- Treatment-Emergent Sexual Dysfunction Related to AntidepressantsJournal of Clinical Psychopharmacology, 2009
- Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive DisorderThe Journal of Clinical Psychiatry, 2009
- Compelling or irrelevant? Using number needed to treat can help decideActa Psychiatrica Scandinavica, 2008
- Show Me the Evidence: Using Number Needed to TreatSouthern Medical Journal, 2007
- Distinct temporal pattern of the effects of the combined serotonin-reuptake inhibitor and 5-HT1A agonist EMD 68843 on the sleep EEG in healthy menPsychopharmacology, 2001